Q32 Bio (QTTB) Total Non-Current Liabilities (2022 - 2026)
Q32 Bio's quarterly Total Non-Current Liabilities came in at $17.4 million in Q1 2026, down 38.18% year-on-year from $28.1 million in Q1 2025, and down 12.14% quarter-over-quarter from $19.8 million in Q4 2025.
Q32 Bio has reported Total Non-Current Liabilities for 5 years, with the latest figure at $17.4 million in Q1 2026.
- For the quarter ending Q1 2026, Total Non-Current Liabilities fell 38.18% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $17.4 million (down 38.18% YoY), and the FY2025 full-year result was $19.8 million, down 37.57% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $17.4 million, down from $19.8 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $48.5 million in Q1 2024, with the low at $17.4 million in Q1 2026.
- Average Total Non-Current Liabilities over 5 years is $30.7 million, with a median of $31.2 million recorded in 2024.
- Year-over-year, Total Non-Current Liabilities advanced 13.57% in 2023 and slumped 42.04% in 2025.
- Tracing QTTB's Total Non-Current Liabilities over 5 years: stood at $37.7 million in 2022, then gained by 13.57% to $42.8 million in 2023, then retreated by 26.1% to $31.7 million in 2024, then plunged by 37.57% to $19.8 million in 2025, then decreased by 12.14% to $17.4 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $17.4 million (Q1 2026), $19.8 million (Q4 2025), and $21.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 11.03 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 42,980.09 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 95.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 110.28 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.87 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 7.32 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.05 Bn |
| 10 | Q32 Bio | 162.94 Mn | 112.19 Mn | - | 17.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.36 Mn |
| Dec 31, 2025 | 19.76 Mn |
| Sep 30, 2025 | 21.23 Mn |
| Jun 30, 2025 | 23.35 Mn |
| Mar 31, 2025 | 28.09 Mn |
| Dec 31, 2024 | 31.66 Mn |
| Sep 30, 2024 | 31.25 Mn |
| Jun 30, 2024 | 35.70 Mn |
| Mar 31, 2024 | 48.45 Mn |
| Dec 31, 2023 | 42.84 Mn |
| Dec 31, 2022 | 37.72 Mn |